Replies to post #430372 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

dennisdave,

So there is an outside chance that you are not considering because right now it may seem too far fetched but here it is. If manufacturing ramp takes NWBO to a forward looking 5,000 plus patients annually (not 2022 but 2023) in Europe ie Sawston @ $200,000, the same in North America and same again in rest of world via Charles Rivers Labs with ongoing expansion you could easily come up with a forward P/E ratio that puts market cap where not expected now especially with off label use demand once approved. Throw in the added value of demand for Direct once L is validated and Phase 1 Direct results are widely disseminated and that forward looking value increases dramatically again as Direct already has a fully enclosed process. The only real price limiting factors at this time may be questions about the manufacturing ramp and how quickly L and Direct can be made commercially available to patients which is being addressed as we speak. Once the runway is laid out the rest will follow quickly. By mid 2022 it’s likely that these questions will be answered and answered favorably much to the surprise of many because it’s not just NWBO involved getting everything ready. Best wishes.